Table 2.
Characteristics of individual patients with pMMR/MSS mCRC retrospectively analyzed in this study.
| No. | Age (year) | Sex | ECOG PS | Primary tumor location | Sites of metastasis when on treatment | KRAS/NRAS/BRAF mutation status | Response and duration on prior Rego (mo) | Combining regimen | No. of cycles | Response |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 48 | M | 0 | Left | Liver, lung | Wt | PD (2) | Rego + Cam | 4 | SD |
| 2 | 62 | M | 1 | Right | Peritoneum, abdominal wall | KRAS Mt | SD (4) | Rego + Cam | 8 | SD |
| 3 | 54 | M | 1 | Right | Liver, abdominal wall, pelvic cavity | Wt | No Prior Rego | Rego + Nivo | 20 | SD |
| 4 | 48 | F | 1 | Left | RPLN, peritoneal cavity | Wt | SD (3) | Rego + Cam | 3 | PD |
| 5 | 48 | M | 0 | Right | Lung, lymph nodes | Wt | No Prior Rego | Rego + Cam | 7 | SD |
| 6 | 57 | F | 2 | Right | Liver, lung | BRAF Mt | SD (4) | Rego + Nivo | 2 | PD |
| 7 | 49 | M | 0 | Left | Liver | KRAS Mt | No Prior Rego | Rego + Nivo | 5 | SD |
| 8 | 63 | F | 1 | Left | Liver | Wt | No Prior Rego | Rego + Cam | 4 | SD |
| 9 | 39 | F | 0 | Left | Liver | KRAS Mt | No Prior Rego | Rego + Cam | 6 | SD |
| 10 | 50 | M | 0 | Right | Liver | Wt | SD (3) | Rego + Tori | 2 | PD |
| 11 | 36 | M | 0 | Right | Lymph nodes, peritoneal cavity, bone | KRAS Mt | No Prior Rego | Rego + Tori | 5 | SD |
| 12 | 56 | M | 1 | Left | Lymph nodes | KRAS Mt | SD (3) | Rego + Nivo | 11 | SD |
| 13 | 62 | M | 2 | Left | Liver | KRAS Mt | No Prior Rego | Rego + Cam | 4 | PD |
| 14 | 37 | M | 2 | Left | Liver, lung | KRAS Mt | No Prior Rego | Rego + Nivo | 2 | PD |
| 15 | 62 | M | 1 | Left | Liver | Wt | SD (4) | Rego + Nivo | 6 | SD |
| 16 | 33 | M | 1 | Left | Lung | KRAS Mt | No Prior Rego | Rego + Sin | 4 | SD |
| 17 | 54 | M | 1 | Left | RPLN, pelvic cavity, bone | Wt | No Prior Rego | Rego + Nivo | 6 | SD |
| 18 | 38 | F | 1 | Left | Lung | KRAS Mt | No Prior Rego | Rego + Cam | 5 | SD |
| 19 | 73 | F | 1 | Left | Lymph nodes, adrenal gland | Wt | No Prior Rego | Rego + Cam | 4 | SD |
| 20 | 48 | M | 1 | Left | Liver, lung | Wt | No Prior Rego | Rego + Nivo | 8 | SD |
| 21 | 51 | M | 1 | Left | Liver, lung | KRAS Mt | No Prior Rego | Rego + Sin | 3 | SD |
| 22 | 36 | M | 1 | Left | Lung | KRAS Mt | PD (2) | Rego + Pem | 9 | SD |
| 23 | 70 | F | 1 | Left | Liver, lung | KRAS Mt | SD (1) | Rego + Cam | 5 | SD |
Cam, camrelizumab; ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; M, male; mo, months; Mt, mutant; Nivo, nivolumab; Pem, pembrolizumab; PD, progressive disease; Rego, regorafenib; RPLN, retroperitoneal lymph node; SD, stable disease; Sin, sintilimab; Tori, toripalimab; Wt, wild-type.